If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the First Trust Morningstar Dividend Leaders ETF (FDL), a passively managed exchange ...

Journal of the National Comprehensive Cancer Network finds that for many commonly used treatment regimens targeting ...

AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical company, develops and sells prescription medications for various health conditions, focusing on chronic autoimmune diseases, oncology ...

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 – jumping from levels of $90 then to around $195 now – vs. an increase of about 50% for the S&P 500 over this ...

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors AML is a genetically heterogeneous disease, ...

In this article, we are going to take a look at where AbbVie Inc (NYSE:ABBV) stands against the other 52-week high stocks. The U.S. stock market has been on a roll, with major indices clocking ...

There are three ways to make image backgrounds transparent on Mac: Using Remove background in Tools, Instant Alpha, and Selection tools. Before following any of the methods given below, make a ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its ...

AbbVie's Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven's Nurtec The top-selling CGRP is Pfizer’s Nurtec, which rang up sales of $928 million last year.

AbbVie shares are nearing $200, likely facing resistance and a potential pullback to test support between $175 and $185. Despite strong dividends and share buybacks, AbbVie’s higher P/E ratio ...

Eli Lilly is exploring whether its newest hit drug could be used to treat psoriasis. AbbVie's newest hit drugs already treat psoriasis, among other conditions. It usually isn't good news for a ...